US › Healthcare

Autolus Therapeutics Ltd (AUTL)

US · Healthcare · Biotechnology

$1.92+2.67%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$45.7M

Revenue YoY

+118.4%

Net profit

$-39.1M

EPS

$-0.15

EPS estimate

$-0.21

Net margin

-85.6%

EPS came in at -0.15 against a street estimate of -0.21 — a beat of 28.6%.

Key statistics

Market cap

$500.4M

Forward P/E

0.0

P/B

6.69

Book value

$5.91

EPS (TTM)

$-1.06

52-week high

$2.58

52-week low

$1.18

50-day MA

$1.91

200-day MA

$1.64

Beta

2.00

Analyst view

Analysts rate Autolus Therapeutics Ltd a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $8.72.

Shareholding

Insiders

18.09%

Institutions

63.43%

Largest institutional holders

Fund	Stake
Mak Capital One LLC	12.63%
Blackstone Inc	7.70%
Syncona Portfolio Ltd.	6.25%
Armistice Capital, LLC	5.94%
Polygon Management Ltd	3.57%
Schroder Investment Management Group	2.94%
Frazier Life Sciences Management, L.P.	1.67%
BNP Paribas Investment Partners SA	1.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Autolus Therapeutics Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.